8.91
1.87%
-0.17
Avalo Therapeutics Inc 주식(AVTX)의 최신 뉴스
BTIG Research Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX) - Defense World
Avalo Therapeutics initiated with a Buy at BTIG - Yahoo Finance
BTIG optimistic on Avalo Therapeutics stock with potential for transformative Phase 2b trial results - Investing.com Canada
(AVTX) Trading Report - Stock Traders Daily
LUCID CAPITAL MARKETS Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - MSN
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 46.9% - MarketBeat
Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk - TipRanks
Trading (AVTX) With Integrated Risk Controls - Stock Traders Daily
RA Capital Management L.P. Takes Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - MarketBeat
Learn to Evaluate (AVTX) using the Charts - Stock Traders Daily
Avalo Therapeutics (FRA:C6K0) Cash From Other Investing Act - GuruFocus.com
Avalo Therapeutics (FRA:C6K0) Cyclically Adjusted PS Ratio : 0.02 (As of Nov. 21, 2024) - GuruFocus.com
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday - MSN
(AVTX) Investment Analysis and Advice - Stock Traders Daily
Orbimed Advisors LLC Acquires New Stake in Avalo Therapeutics Inc - GuruFocus.com
Avalo Therapeutics director June Almenoff acquires $12,749 in stock - Investing.com
Avalo Therapeutics Inc (AVTX) Quarterly 10-Q Report - Quartzy
Avalo Therapeutics receives $69.4M in proceeds from full exercise of private placement warrants - MSN
Avalo Therapeutics secures $69.4 million from warrant exercise By Investing.com - Investing.com Australia
Avalo Therapeutics Closes $69.4 Million Financing - citybiz
Avalo Therapeutics receives $69.4M in proceeds from exercise of warrants - TipRanks
Avalo Therapeutics secures $69.4 million from warrant exercise - Investing.com India
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewswire
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewswire Inc.
Avalo Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Avalo Therapeutics reports Q3 EPS ($2.83) vs ($22.83) last year - TipRanks
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire
Where are the Opportunities in (AVTX) - Stock Traders Daily
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at HC Wainwright - Defense World
When (AVTX) Moves Investors should Listen - Stock Traders Daily
Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa - Investing.com
Avalo Therapeutics maintains Outperform rating from Oppenheimer - Investing.com
Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa By Investing.com - Investing.com UK
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial - GlobeNewswire
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - Yahoo Finance
Ikarian Capital, LLC Adjusts Stake in Avalo Therapeutics Inc - GuruFocus.com
(AVTX) Technical Pivots with Risk Controls - Stock Traders Daily
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 38.1% - Defense World
Avalo Therapeutics: Pioneering Biotech Solutions for Immune Disorders - The China Perspective
Affinity Asset Advisors LLC Acquires 35,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Logos Global Management LP Purchases New Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
How To Trade (AVTX) - Stock Traders Daily
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 7.8% - Defense World
Avalo Therapeutics regains Nasdaq compliance - Investing.com
Avalo Announces Participation in September Investor Conferences - GlobeNewswire
Financial Health Report: Avalo Therapeutics Inc (AVTX)’s Ratios Tell a Tale - The Dwinnex
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 9.6% in July - Defense World
Avalo Therapeutics (FRA:C6K0) Cash From Discontinued Investing Activities : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oppenheimer sees upside in Avalo Therapeutics stock as phase 2 trial nears - Investing.com
Avalo Therapeutics (NASDAQ:AVTX) Releases Earnings Results - Defense World
Avalo Therapeutics Shareholders Back Board and Strategies - TipRanks
Avalo Therapeutics sees cash runway into 2027 - TipRanks
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024 - InvestorPlace
자본화:
|
볼륨(24시간):